SARS-CoV-2, although not being a circulatory virus, spread from the respiratory tract resulting in multiorgan failures and thrombotic complications, the hallmarks of fatal
COVID-19. A convergent contributor could be platelets that beyond
hemostatic functions can carry infectious viruses. Here, we profiled 52 patients with severe
COVID-19 and demonstrated that circulating platelets of 19 out 20 non-survivor patients contain SARS-CoV-2 in robust correlation with fatal outcome. Platelets containing SARS-CoV-2 might originate from bone marrow and lung megakaryocytes (MKs), the platelet precursors, which were found infected by SARS-CoV-2 in
COVID-19 autopsies. Accordingly, MKs undergoing shortened differentiation and expressing anti-viral IFITM1 and IFITM3
RNA as a sign of viral sensing were enriched in the circulation of deadly
COVID-19. Infected MKs reach the lung concomitant with a specific MK-related
cytokine storm rich in
VEGF, PDGF and inflammatory molecules, anticipating fatal outcome. Lung macrophages capture SARS-CoV-2-containing platelets in vivo. The virus contained by platelets is infectious as capture of platelets carrying SARS-CoV-2 propagates
infection to macrophages in vitro, in a process blocked by an anti-GPIIbIIIa
drug. Altogether, platelets containing infectious SARS-CoV-2 alter
COVID-19 pathogenesis and provide a powerful fatality marker. Clinical targeting of platelets might prevent viral spread,
thrombus formation and exacerbated
inflammation at once and increase survival in
COVID-19.